Advanced polymeric dendrimers in the management of Alzheimer's disease |
| |
Authors: | Harshad S. Kapare Ranjitsinh Pawar Vrushali Neve Vrushali Bhalchim Prabhanjan S. Giram |
| |
Affiliation: | Departmant of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Pune, India |
| |
Abstract: | In recent years, advanced polymeric dendrimers have emerged as a promising avenue for AD management. Dendrimers are highly branched, three-dimensional macromolecules with precise nanoarchitectures, making them ideal candidates for the delivery of therapeutic agents and diagnostic tools. Their unique properties, such as well-defined size, multifunctionality, and controlled surface chemistry, allow for the design of targeted and highly efficient drug delivery systems and diagnostic probes. This review aims to provide a comprehensive overview of the potential applications of advanced polymeric dendrimers in the management of Alzheimer's disease. We explored their role in drug delivery, diagnostics, and other therapeutic interventions for AD. Additionally, we will delve into the challenges and opportunities in utilizing dendrimers as a key player in the battle against this devastating disease. The review will begin by discussing the current state of Alzheimer's disease, including its pathological features, clinical manifestations, and existing treatment strategies. It will then transition to an in-depth examination of polymeric dendrimers, highlighting their structural characteristics, synthesis methods, and biocompatibility. Subsequently, the review will delve into the various ways in which dendrimers can be tailored for AD management, including drug encapsulation and delivery, enhanced blood–brain barrier penetration, and targeted diagnostic imaging. Furthermore, we explored the potential benefits of dendrimer-based therapies, such as improved drug efficacy, reduced side effects, and enhanced patient compliance. The review will also address the challenges associated with dendrimer-based approaches, including toxicity concerns, regulatory hurdles, and the need for rigorous clinical evaluation. |
| |
Keywords: | Alzheimer's disease (AD) dendrimers neurodegenerative polyamidoamine (PAMAM) polypropyleneimine (PPI) |
|
|